ACCPL2025-10-012026-03-31ACCPL2026-03-31ACCPL2025-03-31ACCPL2025-04-012026-03-31ACCPL2025-10-012026-03-31in-capmkt:OtherExpenses1MemberACCPL2025-04-012026-03-31in-capmkt:OtherExpenses1MemberACCPL2026-03-31OtherCurrentLiabilitiesDomain1ACCPL2026-03-31OtherNoncurrentAssetsDomain1ACCPL2026-03-31OtherCurrentAssetsDomain1ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain1ACCPL2025-09-30RelatedPartyTransactionDomain1ACCPL2026-03-31RelatedPartyTransactionDomain1ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain2ACCPL2025-09-30RelatedPartyTransactionDomain2ACCPL2026-03-31RelatedPartyTransactionDomain2ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain3ACCPL2025-09-30RelatedPartyTransactionDomain3ACCPL2026-03-31RelatedPartyTransactionDomain3ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain4ACCPL2025-09-30RelatedPartyTransactionDomain4ACCPL2026-03-31RelatedPartyTransactionDomain4ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain5ACCPL2025-09-30RelatedPartyTransactionDomain5ACCPL2026-03-31RelatedPartyTransactionDomain5ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain6ACCPL2025-09-30RelatedPartyTransactionDomain6ACCPL2026-03-31RelatedPartyTransactionDomain6ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain7ACCPL2025-09-30RelatedPartyTransactionDomain7ACCPL2026-03-31RelatedPartyTransactionDomain7ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain8ACCPL2025-09-30RelatedPartyTransactionDomain8ACCPL2026-03-31RelatedPartyTransactionDomain8ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain9ACCPL2025-09-30RelatedPartyTransactionDomain9ACCPL2026-03-31RelatedPartyTransactionDomain9ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain10ACCPL2025-09-30RelatedPartyTransactionDomain10ACCPL2026-03-31RelatedPartyTransactionDomain10ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain11ACCPL2025-09-30RelatedPartyTransactionDomain11ACCPL2026-03-31RelatedPartyTransactionDomain11ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain12ACCPL2025-09-30RelatedPartyTransactionDomain12ACCPL2026-03-31RelatedPartyTransactionDomain12ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain13ACCPL2025-09-30RelatedPartyTransactionDomain13ACCPL2026-03-31RelatedPartyTransactionDomain13ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain14ACCPL2025-09-30RelatedPartyTransactionDomain14ACCPL2026-03-31RelatedPartyTransactionDomain14ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain15ACCPL2025-09-30RelatedPartyTransactionDomain15ACCPL2026-03-31RelatedPartyTransactionDomain15ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain16ACCPL2025-09-30RelatedPartyTransactionDomain16ACCPL2026-03-31RelatedPartyTransactionDomain16ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain17ACCPL2025-09-30RelatedPartyTransactionDomain17ACCPL2026-03-31RelatedPartyTransactionDomain17ACCPL2025-10-012026-03-31RelatedPartyTransactionDomain18ACCPL2025-09-30RelatedPartyTransactionDomain18ACCPL2026-03-31RelatedPartyTransactionDomain18ACCPL2026-03-31Statement1ACCPL2025-10-012026-03-31Statement1ACCPL2026-03-31StatementDynamic1I1Statement1ACCPL2026-03-31StatementDynamic1I2Statement1ACCPL2026-03-31StatementDynamic1I3Statement1ACCPL2026-03-31StatementDynamic1I4Statement1ACCPL2026-03-31StatementDynamic1I5Statement1ACCPL2026-03-31StatementDynamic1I6Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares000000ACCPLNOTLISTEDINE0T8T01010Accretion Pharmaceuticals LimitedSMEEquity2025-04-012026-03-312026-05-082026-05-01INRLakhsHalf YearlyYearlySingle segmentPharmaceutical2026-05-0815:00:002026-05-0815:45:00trueCash Flow IndirectNot applicabletruetrueNANAfalsetrue2024-07-25https://accretionpharma.com/true1falseNot Applicable2025-10-012026-03-31AuditedStandalone4589090008000004597090003501950000-20210000242900004771000811400025825000392985000667240000667240000667240001724300032800017571000491530000004915300049153000111160000104.424.421. The above Audited financial results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 08/05/2026. <BR> 2. The previous periods figures have been regrouped whereever necessary. <BR> 3.The Statutory auditors of the company have carried out an Audit and issued "Independent Auditor's report" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015. <BR> 4.The Company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kind of Drugs, Pharmaceuticals products and related products thereto and which is considered as only reportable primary business segment as per Accounting Standard "Segment Reporting" (AS - 17). As such, no separate disclosure for Segment Reporting is made. <BR> 5.The figures for the half year ended 31st March, 2026 are the balancing figures between the audited figures in respect of full financial year and the year-to-date figures up to the first half year of the financial year. <BR> 6.The company had made an intial public offering (IPO) of 29,46,000 equity shares of face value of Rs. 10 each fully paid up for cash at a price of Rs. 101 per equity shares (including share premium of Rs. 91 per equity share) aggregating to Rs. 29,75,46,000/- The equity shares of the company got listed on NSE Emerge Platform on 21st May, 2025. <BR> 7.Earning per share is not retrospectively effected due to Fresh issue of equity as it is considered as Non-Adjusting event as per AS 4 'Contingencies and Events Occurring After the Balance Sheet Date'. <BR> 8. Statement of Utilization of proceeds from the preferential issue of the Equity Shares is attached herewith as additional disclosure.2025-04-012026-03-31AuditedStandalone89627100019050008981760006941630000-426340004485700084790001211100050369000767345000130831000013083100001308310003337800077800034156000966750000009667500096675000111160000104359250009.039.03Other Expenses25825000Other Expenses5036900011116000043592500005470850000086250002724000001134900011458700015887000417700005765700053500035342000208121000766555000132117000020200001341370000825000256620001606240000283746000224001000402060000554070002571000605931000766555000Repayment / Prepayment of certain borrowings availed by our company: During the period of Listing; an installment of the borrowings has been due for the payment, and the company has paid the said due installment from its own fund and after the listing proceedings received, company has paid off the remaining amount of the borrowings, as stated in the object of the Initial public offer.Other Current Liabilities535000Other Non-current assets25662000Other current Assets25710008479000121110000000000020590000-77649000-107390000-69846000-18205000880008752000-264250000-243660000-112829000000333780000-14620700000-1462070000000000008533800000000000000-8533800000-8533800029754600000017824000000-8479000271243000002712430003969800003969800050800040206000Accretion Pharmaceuticals Limited******Mr. Harshad Nanubhai Rathod******Director and Key Management PersonnelRemuneration5000000No Remark and approved14500000195000Accretion Pharmaceuticals Limited******Mr. Vivek Ashok Kumar Patel******Director and Key Management PersonnelRemuneration5000000No Remark and approved14500000195000Accretion Pharmaceuticals Limited******Mr. Hardik Mukundbhai Prajapati******DirectorRemuneration5000000No Remark and approved14500000195000Accretion Pharmaceuticals Limited******Mr. Mayur Popatlal Sojitra******DirectorRemuneration5000000No Remark and approved14500000195000Accretion Pharmaceuticals Limited******Mrs. Ankita Vivek Patel******Part of Promoter GroupAny other transactionAvailing Services200000No Remark and approved8000000Accretion Pharmaceuticals Limited******Mrs. Hiral Dipen Shah******Part of Promoter GroupAny other transactionSalary800000No Remark and approved638000047000Accretion Pharmaceuticals Limited******Accretion Nutraveda Limited******Directors having Significant Influence and OthersPurchase of goods or services50000000No Remark and approved32020003140000Accretion Pharmaceuticals Limited******Accretion Nutraveda Limited******Directors having Significant Influence and OthersSale of goods or services50000000No Remark and approved500000Accretion Pharmaceuticals Limited******Accretion Nutraveda Limited******Directors having Significant Influence and OthersAny other transactionAdvances / Trade receivables50000000No Remark and approved000Accretion Pharmaceuticals Limited******Accretion Nutraveda Limited******Directors having Significant Influence and OthersAny other transactionAdvances / Trade payables50000000No Remark and approved000Accretion Pharmaceuticals Limited******Accretion INC******Directors having Significant Influence and OthersPurchase of goods or services5000000No Remark and approved000Accretion Pharmaceuticals Limited******Accretion INC******Directors having Significant Influence and OthersSale of goods or services5000000No Remark and approved29800000Accretion Pharmaceuticals Limited******Accretion INC******Directors having Significant Influence and OthersAny other transactionAdvances / Trade receivables1000000No Remark and approved000Accretion Pharmaceuticals Limited******Accretion INC******Directors having Significant Influence and OthersAny other transactionAdvances / Trade payables1000000No Remark and approved000Accretion Pharmaceuticals Limited******Accresha Lifecare Private Limited******Directors having Significant Influence and OthersPurchase of goods or services50000000No Remark and approved000Accretion Pharmaceuticals Limited******Accresha Lifecare Private Limited******Directors having Significant Influence and OthersSale of goods or services100000000No Remark and approved93260001310003230000Accretion Pharmaceuticals Limited******Accresha Lifecare Private Limited******Directors having Significant Influence and OthersAny other transactionAdvances / Trade receivables50000000No Remark and approved000Accretion Pharmaceuticals Limited******Accresha Lifecare Private Limited******Directors having Significant Influence and OthersAny other transactionAdvances / Trade payables50000000No Remark and approved00019349000Public Issues2025-05-222975460002026-03-31falsefalseNo commentsNo commentsVIVEK ASHOKKUMAR PATELManaging DirectorAhmedabad2026-05-08Capital expenditure towards purchase of new equipment/ machineries, etc.Not Applicable269730000269730000Capital Expenditure towards purchase of new equipment / machineries, etc: The Company has utilized the funds for the purchase of new equipment and machinery in accordance with the disclosures made in its Prospectus. Furthermore, an additional amount of Rs. 1.29 lakhs has been utilized from the Companys internal accruals/own funds.Capital expenditure towards upgradation of existing manufacturing facilityNot Applicable465570000465570000Repayment/prepayment of certain borrowings availed by our CompanyNot Applicable9917000099170000Repayment / Prepayment of certain borrowings availed by our company: During the period of Listing; an installment of the borrowings has been due for the payment, and the company has paid the said due installment from its own fund and after the listing proceedings received, company has paid off the remaining amount of the borrowings, as stated in the object of the Initial public offer.Funding working capital requirementsNot Applicable14680000001468000000General Corporate PurposeNot Applicable442970000442970000IPO related expensesNot Applicable230020000230020000